Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517554 · ClinicalTrials.gov registry record
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 120
- Enrollment target
NCT02517554: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02517554 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02517554 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The goal of this research is to evaluate the relative advantage of remote counseling over usual care in community health practices without access to genetic services. We will evaluate ability of remote telemedicine, referred to going forward as TeleGenetic services (phone or videoconferencing), to increase uptake of genetic testing and identification of genetic carriers compared to usual care. Secondly, we will evaluate the advantages of videoconferencing over telephone for delivery of remote genetic services and the short-term and longitudinal outcomes of TeleGenetic services in socio-demographically diverse patients in community practices.
Interventions
- BEHAVIORAL Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site
- BEHAVIORAL Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site
- BEHAVIORAL Patient receives written information on how to find genetic services in their area
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-08 |
| Est. Completion | 2019-11 |
What the finished NCT02517554 record still lists
NCT02517554 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site is the first listed.
NCT02517554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02517554 about?
NCT02517554 is a clinical study titled "A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services". The goal of this research is to evaluate the relative advantage of remote counseling over usual care in community health practices without access to genetic services. We will evaluate ability of remote telemedicine, referred to going forward as TeleGenetic services (phone or videoconferencing), to i...
What is the current status of trial NCT02517554?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2015-08. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02517554?
The interventions under investigation include: Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site (BEHAVIORAL), Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site (BEHAVIORAL), Patient receives written information on how to find genetic services in their area (BEHAVIORAL).
Who is sponsoring clinical trial NCT02517554?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia